Circular RNAs as Potential Biomarkers in Breast Cancer
Article 2022 en
Authors
FP
Fatima Domenica Elisa De Palma
FS
Francesco Salvatore
JP
Jonathan Pol
Abstract
1 min read
Due to the high heterogeneity and initially asymptomatic nature of breast cancer (BC), the management of this disease depends on imaging together with immunohistochemical and molecular evaluations. These tests allow early detection of BC and patient stratification as they guide clinicians in prognostication and treatment decision-making. Circular RNAs (circRNAs) represent a class of newly identified long non-coding RNAs. These molecules have been described as key regulators of breast carcinogenesis and progression. Moreover, circRNAs play a role in drug resistance and are associated with clinicopathological features in BC. Accumulating evidence reveals a clinical interest in deregulated circRNAs as diagnostic, prognostic and predictive biomarkers. Furthermore, due to their covalently closed structure, circRNAs are highly stable and easily detectable in body fluids, making them ideal candidates for use as non-invasive biomarkers. Herein, we provide an overview of the biogenesis and pleiotropic functions of circRNAs, and report on their clinical relevance in BC.
Daniel Ortega-Álvarez, David Tébar-García, Marta Casado-Peláez, E Castillo-Agea, J Balibrea-Rull, David Olivares-Osuna, D Pérez-Parra, Cristina Guardia, Eva Musulén, Elena Vinuesa-Pitarch, Elsa Sánchez‐López, Fátima Postigo-Corrales, Ester Ballana, Anna Martínez‐Cardús, Mireia Margelí Vila, Manel Esteller, PL Fernández-Ruiz, Ginés Luengo‐Gil, Elisabetta Mereu, Eva María Galán‐Moya, Verónica Rodilla
Maria Papatsirou, Christos K. Kontos, Ioannis Ntanasis-Stathopoulos, Panagiotis Tsiakanikas, Christine‐Ivy Liacos, Maria Gavriatopoulou, Efstathios Kastritis, Meletios A Dimopoulos, Jérôme Moreaux, Andreas Scorilas, Evangelos Terpos
Discussion(0)
No comments yet. Be the first to comment.